AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05955664 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI indlcuding DTI
Description: A novel technique in MR imaging, which allows tracking of the pelvic floor muscle fibers, Diffusion Tensor Imaging (DTI) will be performed in addition to the standard scanning protocol. We think that MRI with DTI is superior to routine MRI in visualization of LAM.
Study NCT05955664 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Pelvic floor ultrasound.
Description: The patient will be scanned in a supine position and the probe is inserted into the vagina in the neutral position to avoid excessive pressure on surrounding structures to avoid distortion of the anatomy. The 3D data automatic acquisition takes approximately 70 seconds.~The analysis of the ultrasound images will be performed on the Trust computers by Radiologists experienced in pelvic floor ultrasound.~Participant will be asked to complete a VAS score for the US.
Study NCT05955664 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor ultrasound.
Description: The patient will be scanned in a supine position and the probe is inserted into the vagina in the neutral position to avoid excessive pressure on surrounding structures to avoid distortion of the anatomy. The 3D data automatic acquisition takes approximately 70 seconds.~The analysis of the ultrasound images will be performed on the Trust computers by Radiologists experienced in pelvic floor ultrasound.~Participant will be asked to complete a VAS score for the US.
Study NCT03517098 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The ERAS group
Description: ERAS pathway for orthopedic surgeons:~1. Shortened preoperative fasting from intake.~2. Preoperative tranexamic acid administration.~3. No indwelling catheters.~4. No tourniquet used for TKA.~5. No drainage tube.~6. Application of the low molecular heparin 6 hours after the operation.~ERAS pathway for anesthesiologist:~1. Intravenous 20 mg of dexamethasone before anesthetic induction.~2. Anesthesia will be induced with small dose of long-acting opioids such as sulfentanil, or without long-acting opioids at all.~3. Laryngeal mask for airway.~4. Anesthesia will be maintained with short-acting anesthetic agents such as desflurane, sevoflurane, or propofol, with continuous remifentanil , and BIS value will be kept between 40 to 60 during procedure.~5. Incision infiltration with 40-50ml of 0.2% ropivacaine, and no patient controlled intravenous analgesia devices will be applied.
Study NCT03517098 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: The non-ERAS group
Description: Patients undergoing THA or TKA will receive conventional care according to different participating center, and there's no standard protocol for pre-operative management, anesthetic technique or medication choice, postoperative analgesia or food intake, or catheters indwelling.
Study NCT05553769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training, detraining, retraining
Description: Participants (healthy untrained men and women, age 18-40) start with a 3-week familiarization and baseline measurement period. After that, they are randomized to two intervention groups, where other group will conduct 10-week RT intervention and a 10-week DT period and again the exact same 10-week RT intervention again whereas the other group start with a 10-week non-training period and then continues with a 20-week RT intervention. RT consists of two training sessions per week of total body workouts. Same measurements are conducted for both groups with the same time intervals.
Study NCT04234191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Description: Buprenorphine/naloxone is an opioid agonist treatment for opioid use disorder. It is administered via sublingual tablet form.
Study NCT04234191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine/naloxone
Description: Buprenorphine/naloxone is an opioid agonist treatment for opioid use disorder. It is administered via sublingual tablet form.
Study NCT04234191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Hydromorphone is an opioid used for managing pain, craving, and withdrawal. It is administered orally via tablet or liquid form; or administered intravenously, subcutaneously, or intramuscularly via liquid form.
Study NCT06259721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD1 antibody, nimotuzumab and capecitabine
Description: Combination phase Anti-PD1 monoclonal antibody: Choose one of the anti-PD-1 monoclonal antibody drugs reimbursed by medical insurance, toripalimab (240mg), camrelizumab (200mg), tislelizumab (200mg) or others; Intravenous infusion, every 3 weeks .~Nimotuzumab:: In the first 6 cycles, 200 mg, intravenous infusion, every 1 week, and 400 mg is administered for the first time.~Capecitabine: 1000 mg/m2, orally twice daily on days 1-14, every 3 weeks~Maintenance phase:~Anti-PD1 monoclonal antibody: anti-PD-1 monoclonal antibody drugs, Intravenous infusion, every 3 weeks.~Nimotuzumab treatment: 400 mg, intravenous infusion, every 3 weeks. Capecitabine: 1000 mg/m2, orally twice daily on days 1-14, every 3 weeks；~The duration of treatment is 1 year or until intolerable toxic reactions occur, or disease progresses, or the patient withdraws consent, or the investigator determines that the patient needs to withdraw from treatment.
Study NCT05376956 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique
Description: Using Muscle Energy Technique in Individuals With Hamstring Shortness
Study NCT05376956 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Proprioception neuromuscular facilitation (PNF)
Description: Using proprioception neuromuscular facilitation (PNF) in Individuals With Hamstring Shortness
Study NCT06077201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HBCR hands-off
Description: Home-based cardiac rehabilitation intervention facilitated by a custom app to deliver education, counseling on healthy living and modification of risk factors, mindfulness, and physical activity guidance.
Study NCT06275698 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Manuka honey MGO 1000
Description: Natural Manuka honey, produced in New Zealand. With MGO content ≥ 1000.
Study NCT06275698 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar-based syrup, thickened with sodium alginate and flavoured with honey flavouring
Description: Sugar-based syrup, thickened with sodium alginate and flavoured with honey flavouring, 15ml, three times a day, for 14 days.~To be kept on the tongue for at least 10 seconds prior to swallowing.
Study NCT05199662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous tenecteplase
Description: Intravenous tenecteplase (TNK). Patients will receive intravenous TNK (0.25mg/kg, maximum 25mg, administered as a bolus over 5 seconds).
Study NCT05199662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching IV TNK
Study NCT05384574 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: daily supplementation of cholecalciferol, 10 000 IU, during 14 days
Study NCT06077201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HBCR interactive
Description: Home-based cardiac rehabilitation intervention facilitated by a custom app to deliver education, counseling on healthy living and modification of risk factors, mindfulness, and physical activity guidance. Additionally, there are periodic video calls with an exercise physiologist.
Study NCT06456515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib and Sintilimab in combination with electroacupuncture
Description: Regorafenib, take for 2 weeks and stop for 1 week; Sintilimab, intravenous, every 3 weeks; Electroacupuncture was performed 1 day before, on the day of, and on the 2nd day after each cycle of Sintilimab administration, and patients completed 3 treatments in week 1, followed by 1 treatment per week for 2 weeks, with 5 treatments per dosing cycle.
Study NCT05441943 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphovenous anastomosis
Description: Pre-operative planning prior to lymphovenous anastomosis using ICG lymphography and ultra high frequency ultrasound for mapping of applicable vessels.~During surgery, mapped vessels are freely dissected and anastomosed.
Study NCT06353360 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields
Description: Tumor Treating Fields will be administered continuously with a planned ≥ 18 h per day, starting on the Day 1 of cycle 1 (C1D1), throughout the entire course of treatment.
Study NCT06353360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab will be given 300 mg intravenously every 4 weeks beginning on Day 1 of Cycle 2 of adjuvant TMZ. The Tislelizumab treatment should be continued until confirmed PD, unacceptable toxicity, or finished Tislelizumab treatment for other reasons.
Study NCT06353360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: The patients will carry out 6 cycles of TMZ adjuvant chemotherapy according to the instructions. The dosage of TMZ is 150-200 mg/(m2·d), daily for 5 days followed by 23 days without treatment, the treatment cycle is 28 days. The initial dose of cycle 1 is 150 mg/(m2·d), if patients do not experience TMZ chemotherapy toxicity, the dose should be increased to 200 mg/(m2·d) in subsequent treatment cycles. After 6 cycles of TMZ adjuvant chemotherapy, if the patients do not experience disease progression, it is recommended to continue TMZ adjuvant chemotherapy, or treated according to investigators' recommendations. The TMZ treatment should be continued until confirmed progressive disease (PD), unacceptable toxicity, or finished TMZ treatment for other reasons.
Study NCT05963243 — intervention group
Intervention type: OTHER
Intervention: Ultrasound Scans
Description: Ultrasound scans collected by experts in ultrasound-guided regional anaesthesia.
Study NCT05980195 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Description: Hyperbaric oxygen therapy for 30 times within 50 days
Study NCT05980195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard medical treatment
Description: Standard medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 3 months after stenting).~Other Name: Dual antiplatelet therapy for 3 months
Study NCT05980195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical treatment
Description: Standard medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 3 months after stenting).~Other Name: Dual antiplatelet therapy for 3 months
Study NCT05980195 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk factor management
Description: Management of risk factors including hypertension, diabetes, lipoprotein metabolism disorder, smoking and exercise
Study NCT05980195 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Risk factor management
Description: Management of risk factors including hypertension, diabetes, lipoprotein metabolism disorder, smoking and exercise
Study NCT05792007 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biological sampling in patients
Description: blood and bone marrow samples from patients with Acute Leulemia.
Study NCT05792007 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biological sampling in control patients
Description: blood and bone marrow samples from children undergoing orthopedic surgery exposing the bone marrow.(osteotomy of the pelvis).
Study NCT04822818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEVA+SOC
Description: Bevacizumab : 7.5 mg / kg (with a maximum of 750 mg) on day 1 (D1) SOC : patients will receive the best of standard of care including corticosteroids, anticoagulant, antibiotics and tociluzimab
Study NCT04822818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: patients will receive the best of standard of care including corticosteroids, anticoagulant, antibiotics and tociluzimab
Study NCT06051955 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: oral sodium sulfate
Description: All participants enrolled in this study will use Oral Sodium Sulfate as their bowel cleansing agent.
Study NCT06427863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ornidazole
Description: Patients will receive three consecutive enemas of ornidazole 0.5g+50ml saline through the TET tube, followed by WMT treatment once daily for a duration of 3 days
Study NCT06427863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive three consecutive enemas of placebo of equal volume through the TET tube, followed by WMT treatment once daily for a duration of 3 days
Study NCT04731753 — intervention group
Intervention type: DEVICE
Intervention: mechanical debridement
Description: The mechanical debridement is performed using the debridement pad Cutimed DebriClean. After the pad is moistened with wound-cleansing solution, the wound is cleaned using circular movements while applying gentle pressure.
Study NCT05613296 — intervention group
Intervention type: DRUG
Intervention: Fostamatinib
Description: Patients with Chronic ITP, refractory to other treatment who received at least one dose of Fostamatinib outside clinical trials in Italy will be enrolled and observed for at least 6 months.
Study NCT06035809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART
Description: A movement and body-based intervention in which participants are encouraged to explore the use of sensory equipment, which may help reduce symptoms related to psychological trauma/PTSD. Sensory equipment includes exercise balls, mini-trampoline, weighted blankets, and a hammock swing.
Study NCT06154876 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cough assist device
Description: Cough assist device Cough Assist clears secretions from the lungs by gradually applying positive air pressure to the airway and then rapidly shifting to negative air pressure . The resulting high expiratory flow simulates a deep, natural cough.~Designed chest physical therapy Percussion, vibration, end expiratory pressure and bed mobility exercise.
Study NCT06154876 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cough assist device
Description: Cough assist device Cough Assist clears secretions from the lungs by gradually applying positive air pressure to the airway and then rapidly shifting to negative air pressure . The resulting high expiratory flow simulates a deep, natural cough.~Designed chest physical therapy Percussion, vibration, end expiratory pressure and bed mobility exercise.
Study NCT05715437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine plus Normal Saline
Description: Effect of Bupivacain and ketamine and is superior to Bupivacaine and Normal Saline in terms of providing better pain control for 48 hours postoperatively after TKA.
Study NCT05715437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain and ketamine
Description: Effect of Bupivacain and ketamine and is superior to Bupivacaine and Normal Saline in terms of providing better pain control for 48 hours postoperatively after TKA.
Study NCT06424015 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid and heparin
Description: Intralipid (20%, 0.011ml/kg/min; Baxter, Healthcare, Deerfield, IL) and heparin (200 units prime, 0.2 unit/kg/min continuous) will be infused to induce acute insulin resistance
Study NCT06525610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periprosthetic Fracture Knee Repaired CT Scans
Description: We will be assessing the use of weight-bearing CT, specifically its imaging, with RSA-like software, for analyzing fracture healing over time for a periprosthetic distal knee fracture.
Study NCT04780802 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: The balloon catheter is placed at the various arterial feeders of the tumor
Description: use of a balloon catheter for providing balloon occlusion, in addition to the standard microcatheter for drug delivery, both catheters are to be placed in parallel through a single guide catheter. Only one arterial puncture wound is involved. The inflated balloon provides temporary occlusion of all arterial tumor feeders except for the one which is selectively catheterized with a microcatheter for delivery of the therapeutic agent. The therapeutic agent consists of Lipiodol mixed with a chemotherapeutic drug, it is delivered through the microcatheter under fluoroscopic control.
Study NCT04911647 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP using plastic stent
Description: Insertion of plastic stent (plastic stent with inner diameter 1.8mm or more) in the biliary obstruction will be performed using ERCP in the patients with the pancreatic cancer undergoing neoadjuvant therapy.
Study NCT04911647 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ERCP using metal stent
Description: Insertion of metal stent (full covered self-expandable metal stent) in the biliary obstruction will be performed using ERCP in the patients with the pancreatic cancer undergoing neoadjuvant therapy.
Study NCT04695353 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemedicine: Virtual visits (videoconferences, texts)
Description: Patients will receive clinical care by using telemedicine (virtual visits)
Study NCT06186908 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Saliva obtaining
Description: The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
Study NCT06433102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual perceptual training based on the lateral masking paradigm
Description: Visual perceptual training is a novel rehabilitation approach aimed at enhancing visual performance through practice of visual tasks. Patients received visual perceptual training based on the lateral masking paradigm every other day. Each training session consisted of 9 stages, totaling 900 trials, lasting 35 to 45 minutes. The stimuli consisted of a central Gabor patch with relatively low contrast positioned in the central fixation area, along with co-linear high-contrast Gabor patches distributed above and below the central stimulus. These stimuli were presented on a Liquid Crystal Display (LCD) monitor, with a training distance of 150 cm.
Study NCT06353633 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: formula
Description: The calories needed by the person are calculated and half of the calories are provided by formulas and the other half based on the elimination diet
Study NCT06353633 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exclusion diet
Description: In this group, only the elimination diet is considered as an intervention
Study NCT04709679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MicroPulse TransScleral CycloPhotoCoagulation
Description: A laser power of 2000- 2500 mW, a laser duration time of 50 to 80 sec per hemifield and varying da number of sweeps per hemifield 3, 4 or 5 will be randomized between patients
Study NCT05170477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: apical patency
Description: In Gp A, apical patency will be maintained till obturation using electronic apex locator confirmed radiographically. Finally, Root canals will be obturated using cold lateral compaction technique. The molars will be permanently restored using composite resin restoration and will be scheduled for extra coronal restoration.
Study NCT06424015 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline will be infused
Study NCT03473769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vital Signs at 2 Hours
Description: Patients vital signs assessed at 2 hours of arrival at ICU
Study NCT03473769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Confusion Assessment method for the ICU (CAM-ICU)
Description: patient must have altered mental status/fluctuating course and inattention, and either disorganized thinking or altered level of consciousness to be CAM positive; these features are determined by observing the patient during bedside cognitive testing.
Study NCT06633471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Two test formulations for the treatment of DED are being compared against the approved OTC formulation (Systane Ultra) and saline (placebo).
Description: Rain and Mist are the test formulations. Systane Ultra is an approved OTC formulation. Saline is the placebo.
Study NCT06633471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Two test formulations for the treatment of DED are being compared against the approved OTC formulation (Systane Ultra) and saline (placebo).
Description: Rain and Mist are the test formulations. Systane Ultra is an approved OTC formulation. Saline is the placebo.
Study NCT06633471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Two test formulations for the treatment of DED are being compared against the approved OTC formulation (Systane Ultra) and saline (placebo).
Description: Rain and Mist are the test formulations. Systane Ultra is an approved OTC formulation. Saline is the placebo.